Abstract:The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is a global crisis; however, our current understanding of the host immune response to SARS-CoV-2 infection remains limited. Herein, we performed RNA sequencing using peripheral blood from acute and convalescent patients and interrogated the dynamic changes of adaptive immune response to SARS-CoV-2 infection over time. Our results revealed numerous alterations in these cohorts in terms of gene expression profiles and the features of immune repertoire. Moreover, a machine learning method was developed and resulted in the identification of five independent biomarkers and a collection of biomarkers that could accurately differentiate and predict the development of COVID-19. Interestingly, the increased expression of one of these biomarkers, UCHL1 , a molecule related to nervous system damage, was associated with the clustering of severe symptoms. Importantly, analyses on immune repertoire metrics revealed the distinct kinetics of T-cell and B-cell responses to SARS-CoV-2 infection, with B-cell response plateaued in the acute phase and declined thereafter, whereas T-cell response can be maintained for up to 6 months post-infection onset and T-cell clonality was positively correlated with the serum level of anti-SARS-CoV-2 IgG. Together, the significantly altered genes or biomarkers, as well as the abnormally high levels of B-cell response in acute infection, may contribute to the pathogenesis of COVID-19 through mediating inflammation and immune responses, whereas prolonged T-cell response in the convalescents might help these patients in preventing reinfection. Thus, our findings could provide insight into the underlying molecular mechanism of host immune response to COVID-19 and facilitate the development of novel therapeutic strategies and effective vaccines.

Immune suppression in the early stage of COVID-19 disease

Overly Exuberant Innate Immune Response to SARS-CoV-2 Infection

Proteomics Investigation of Diverse Serological Patterns in COVID-19

Analysis of the Dynamic Relationship Between Immune Profiles and the Clinical Features of Patients with COVID-19

Inflammation and Antiviral Immune Response Associated With Severe Progression of COVID-19

Immune Response Pattern Across the Asymptomatic, Symptomatic and Convalescent Periods of COVID-19

Serum Protein Profiling Reveals a Landscape of Inflammation and Immune Signaling in Early-stage COVID-19 Infection

Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients

Postmortem high-dimensional immune profiling of severe COVID-19 patients reveals distinct patterns of immunosuppression and immunoactivation

Proteomic Analysis Identifies Prolonged Disturbances in Pathways Related to Cholesterol Metabolism and Myocardium Function in the COVID-19 Recovery Stage

Pathological features of COVID-19-associated lung injury: a preliminary proteomics report based on clinical samples

Longitudinal Serum Proteome Characterization of COVID-19 Patients With Different Severities Revealed Potential Therapeutic Strategies

Immune Characteristic Genes and Neutrophil Immune Transformation Studies in Severe COVID-19

COVID-19: immunopathogenesis and Immunotherapeutics

Integrating longitudinal clinical laboratory tests with targeted proteomic and transcriptomic analyses reveal the landscape of host responses in COVID-19

Biomarkers and Immune Repertoire Metrics Identified by Peripheral Blood Transcriptomic Sequencing Reveal the Pathogenesis of COVID-19

Proteomic and metabolomic profiling of urine uncovers immune responses in patients with COVID-19

A Urinary Proteomic Landscape of COVID-19 Progression Identifies Signaling Pathways and Therapeutic Options.

COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas

Single-cell landscape of immunological responses in patients with COVID-19

Downregulated Gene Expression Spectrum and Immune Responses Changed During the Disease Progression in Patients With COVID-19